Therapix

63 articles about Therapix

• Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical

  7/12/2018

  Therapix Biosciences Ltd. announced that it has signed a non-binding term sheet with CURE Pharmaceutical for the transfer to CURE of the non-pain assets of Therapix, subject to the fulfillment of the certain conditions.

• Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

  7/11/2018

  CURE Pharmaceutical announced that it has signed a term sheet with Therapix Biosciences Ltd.

• Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug

  6/5/2018

  -And the Establishment of Center of Excellence for Sleep and Pain Research and Data Mining Agreement with Maccabi Healthcare Services-

• Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update

  5/31/2018

  Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, issued today its financial summary - first quarter 2018 vs. first quarter 2017

• Therapix Biosciences Issues CEO's Letter to Shareholders

  5/15/2018

  Therapix Biosciences Ltd. (Nasdaq: TRPX) issued today a letter to its shareholders, from the CEO and chairman of the company.

• Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program

  4/9/2018

  Study meets its primary endpoint

• Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

  2/7/2018

  Therapix announced today that it has held a pre-Investigational New Drug communication with the FDA to discuss the regulatory pathway for the development of THX-110 for the treatment of Tourette Syndrome.

• Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018

  1/9/2018

  This new subsidiary will complement the Company's cannabinoid-based drug development strategy.

• Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

  12/4/2017

  The study is sponsored by Therapix and led by Michael H. Bloch, M.D., Associate Professor at the Yale University Child Study Center, and James F. Leckman, M.D., Ph.D., Neison Harris Professor in the Child Study Center and Professor of Child Psychiatry at Yale University.

• Therapix Biosciences Spotlighted in Financial and Trade Media Outlets

  11/21/2017

  Therapix has received positive media coverage in a variety of financial and trade media outlets.

• Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

  11/10/2017

  Therapix plans to initiate a preclinical study during the fourth quarter to evaluate the opioid-sparing effect of these compounds in a rat model.

• Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update

  11/9/2017

  The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs.

• Cure Pharmaceutical Enters Into Product Development Agreement With Therapix Biosciences To Develop Cannabinoid-Based Product for Sleep Disorders

  11/7/2017

  This agreement is an extension of the recently announced partnership between CURE, Therapix and Israel’s Assuta Medical Centers, Ltd.

• Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017

  11/3/2017

  Therapix announced today that it will host a conference call and webcast on Thursday, November 9, 2017, to discuss results for the period ended September 30, 2017 and to provide an update on current developments with respect to its clinical programs.

• Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim CEO

  11/2/2017

  Therapix has appointed Ascher Shmulewitz, M.D., Ph.D., the Company's Chairman of the Board of Directors, to the role of Interim CEO, effective immediately.

• Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center

  10/30/2017

  Therapix has initiated non-clinical studies to evaluate the efficacy of its proprietary compound THX-150, a pharma composition of dronabinol in collaboration with the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center.

• Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea

  10/18/2017

  Therapix signed an agreement with Assuta Medical Center, the largest hospital network and private healthcare provider in Israel, to conduct a Phase IIa, sponsor-initiated trial.

• Therapix Signs Formulation Development And Clinical Manufacturing Agreement With Catalent For THX-TS01

  10/6/2017

• Therapix's First-In-Class Therapy Demonstrates Reversal Of Age-Related Cognitive Impairment In Pre-Clinical Study

  9/27/2017

• Therapix Reports Second Quarter 2017 Financial Results and Provides Business Update

  8/10/2017